847 related articles for article (PubMed ID: 25431052)
21. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
[TBL] [Abstract][Full Text] [Related]
23. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
[TBL] [Abstract][Full Text] [Related]
27. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.
Kremer JM; Genovese MC; Keystone E; Taylor PC; Zuckerman SH; Ruotolo G; Schlichting DE; Crotzer VL; Nantz E; Beattie SD; Macias WL
Arthritis Rheumatol; 2017 May; 69(5):943-952. PubMed ID: 28029752
[TBL] [Abstract][Full Text] [Related]
28. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
[TBL] [Abstract][Full Text] [Related]
29. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang F; Luo ZC
BioDrugs; 2018 Oct; 32(5):415-423. PubMed ID: 30203252
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
35. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Genovese MC; Kremer JM; Kartman CE; Schlichting DE; Xie L; Carmack T; Pantojas C; Sanchez Burson J; Tony HP; Macias WL; Rooney TP; Smolen JS
Rheumatology (Oxford); 2018 May; 57(5):900-908. PubMed ID: 29415145
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
[TBL] [Abstract][Full Text] [Related]
37. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
Takeuchi T; Genovese MC; Haraoui B; Li Z; Xie L; Klar R; Pinto-Correia A; Otawa S; Lopez-Romero P; de la Torre I; Macias W; Rooney TP; Smolen JS
Ann Rheum Dis; 2019 Feb; 78(2):171-178. PubMed ID: 30194275
[TBL] [Abstract][Full Text] [Related]
38. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
[TBL] [Abstract][Full Text] [Related]
40. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
